Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03983980
Other study ID # DMVT-505-3002
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date June 6, 2019
Est. completion date May 29, 2020

Study information

Verified date September 2022
Source Dermavant Sciences, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized double-blind vehicle-controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% once daily for the treatment of plaque psoriasis in adults. Approximately 500 adult subjects with plaque psoriasis will be randomized 2:1 to receive either tapinarof cream, 1% or matching vehicle cream once daily for 12 weeks.


Description:

This study is a 12-week double-blind, vehicle-controlled treatment study in which subjects will be randomized to receive tapinarof cream, 1% or vehicle cream once daily for 12 weeks. At the end of the 12-week study treatment, qualified subjects completing the study will have the option to enter a separate open-label, long-term safety and efficacy study for an additional 40 weeks of treatment with tapinarof cream, 1%. Subjects who do not enroll in the open-label long-term study will complete a follow-up visit approximately 4 weeks after end of treatment in this study (at Week 16).


Recruitment information / eligibility

Status Completed
Enrollment 515
Est. completion date May 29, 2020
Est. primary completion date May 13, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Male and female subjects ages 18 to 75 years with clinical diagnosis of chronic plaque psoriasis and stable disease for at least 6 months prior to the study. - BSA involvement = 3% and = 20% - A PGA score of 2 (mild), 3 (moderate) or 4 (severe) at screening and baseline - Females of child bearing potential and male subjects who are engaging in sexual activity that could lead to pregnancy agree to follow the specified contraceptive guidance throughout the study, including screening, during the treatment period, and for at least 4 weeks after the last exposure to study treatment - Capable of giving written informed consent Exclusion Criteria: - Psoriasis other than plaque variant - Any sign of infection of any of the psoriatic lesions - Concurrent conditions or history of other diseases: - Immunocompromised at Screening - Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to the Baseline visit - Acute active bacterial, fungal, or viral (herpes simplex, herpes zoster, chicken pox) skin infection within 1 week prior to the Baseline visit - Significant dermatologic or inflammatory condition other than plaque psoriasis that, in the Investigator's opinion, would make it difficult to interpret data or assessments during the study - Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) = 1.5x the upper limit of normal (ULN) - Total bilirubin > 1.5 x ULN; total bilirubin > ULN and = 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35% - Corrected QT interval > 475 - Current or chronic history of liver disease, known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones), presence of hepatitis B surface antigen (HBsAg), or positive hepatitis C antibody test result, or a positive anti-hepatitis B core antigen (anti-HBc) result - Ultraviolet (UV) light therapy or prolonged exposure to natural or artificial sources of UV radiation within 4 weeks prior to the Baseline visit and/or plans to have such exposures during the study which could potentially impact the subject's psoriasis - Use of any prohibited medication within the indicated period before the first dose of study drug - Within a minimum of 5 half-lives for biologic agents: - Within 4 weeks for systemic immunosuppressive or immunomodulating agents, fumaric acid derivatives, vitamin D3 and analogs, retinoids, psolarens, corticosteroids, adrenocorticotropic hormone analogs, and tazarotene - 2 weeks for immunizations with a live viral component; drugs known to possibly worsen psoriasis, unless on a stable dose for > 12 weeks - With the exception of non-medicated emollients, 2 weeks for topical treatments including corticosteroids, immunomodulators, anthralin (dithranol), vitamin D derivatives or coal tar. - Pregnant females or lactating females - History of sensitivity to the study drugs, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates the subject's participation in the study - The subject has received an investigational product within 30 days, 5 half-lives, or twice the duration of the biological effect of the study drug (whichever is longer) prior to first dose of study drug - Current or a history of cancer within 5 years except for fully excised skin basal cell carcinoma, squamous cell carcinoma or carcinoma in situ of the cervix - Subjects with active infection that required oral, intramuscular, or intravenous administration of antibiotics, antifungal or antiviral agents within 7 days of Baseline/Day 1 - Previous known participation in a clinical study with tapinarof - Evidence of significant hepatic, renal, respiratory, endocrine, hematologic, neurologic, psychiatric, or CV system abnormalities or laboratory abnormality that will affect the health of the subject or interfere with interpretation of the results

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tapinarof
Tapinarof cream, 1%, applied once daily
Vehicle Cream
Vehicle cream applied once daily

Locations

Country Name City State
Canada Dermavant Investigative Site Edmonton Alberta
Canada Dermavant Investigative Site Etobicoke Ontario
Canada Dermavant Investigative Site Hamilton Ontario
Canada Dermavant Investigative Site Markham Ontario
Canada Dermavant Investigative Site Oakville Ontario
Canada Dermavant Investigative Site Ottawa Ontario
Canada Dermavant Investigative Site Surrey Bristish Columbia
Canada Dermavant Investigative Site Surrey Bristish Columbia
United States Dermavant Investigative Site Bay City Michigan
United States Dermavant Investigative Site Beachwood Ohio
United States Dermavant Investigative Site Bexley Ohio
United States Dermavant Investigative Site Boise Idaho
United States Dermavant Investigative Site Boston Massachusetts
United States Dermavant Investigative Site Boynton Beach Florida
United States Dermavant Investigative Site Charleston South Carolina
United States Dermavant Investigative Site Denver Colorado
United States Dermavant Investigative Site Detroit Michigan
United States Dermavant Investigative Site East Windsor New Jersey
United States Dermavant Investigative Site Fort Gratiot Michigan
United States Dermavant Investigative Site Fort Smith Arkansas
United States Dermavant Investigative Site Fountain Valley California
United States Dermavant Investigative Site Fremont California
United States Dermavant Investigative Site Fridley Minnesota
United States Dermavant Investigative Site Hackensack New Jersey
United States Dermavant Investigative Site Houston Texas
United States Dermavant Investigative Site Las Vegas Nevada
United States Dermavant Investigative Site Los Angeles California
United States Dermavant Investigative Site Louisville Kentucky
United States Dermavant Investigative Site Margate Florida
United States Dermavant Investigative Site Metairie Louisiana
United States Dermavant Investigative Site Miami Florida
United States Dermavant Investigative Site Nashville Tennessee
United States Dermavant Investigative Site Norfolk Virginia
United States Dermavant Investigative Site Oceanside California
United States Dermavant Investigative Site Omaha Nebraska
United States Dermavant Investigative Site Overland Park Kansas
United States Dermavant Investigative Site Owensboro Kentucky
United States Dermavant Investigative Site Pflugerville Texas
United States Dermavant Investigative Site Plainfield Indiana
United States Dermavant Investigative Site Plano Texas
United States Dermavant Investigative Site Portland Oregon
United States Dermavant Investigative Site Rolling Meadows Illinois
United States Dermavant Investigative Site San Antonio Texas
United States Dermavant Investigative Site San Diego California
United States Dermavant Investigative Site Santa Monica California
United States Dermavant Investigative Site Spokane Washington
United States Dermavant Investigative Site Stony Brook New York
United States Dermavant Investigative Site Webster Texas
United States Dermavant Investigative Site Wilmington North Carolina
United States Dermavant Investigative Site Winston-Salem North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Dermavant Sciences GmbH IQVIA Biotech

Countries where clinical trial is conducted

United States,  Canada, 

References & Publications (1)

Lebwohl MG, Stein Gold L, Strober B, Papp KA, Armstrong AW, Bagel J, Kircik L, Ehst B, Hong HC, Soung J, Fromowitz J, Guenthner S, Piscitelli SC, Rubenstein DS, Brown PM, Tallman AM, Bissonnette R. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. N Engl J Med. 2021 Dec 9;385(24):2219-2229. doi: 10.1056/NEJMoa2103629. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation The PGA is a clinical tool for assessing the current state/severity of a subject's psoriasis at a given timepoint. A static 5-point scale is used to grade lesions on the clinical characteristics of erythema, scaling, and plaque thickness/elevation. The PGA ranges from 0 to 4, and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher PGA scores represent more severe disease. Analyses were done using multiple imputation Baseline to Week 12
Secondary Percent of Subjects With = 75% Improvement in Psoriasis Area and Severity Index (PASI) From Baseline at Week 12. Analyses Were Done Using Multiple Imputation. The Psoriasis Area and Severity Index (PASI) scoring system combines the assessment of lesion severity and extent of affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, and legs). Each area is assessed for 3 signs: erythema (redness), induration (plaque thickness), and scale. The severity of each sign in each body area is assessed and scored independently using a 5-point scale, where 0=none, 1=slight, 2=mild, 3=moderate, 4=severe. Each area is also assessed for percent of skin involved: 0 = (0%), 1 = (1-<10%), 2 = (10-<30%), 3 = (30-<50%), 4 = (50 -<70%), 5 = (70-<90%), 6 = (90-100%). The individual scores are multiplied by a weighted factor for each body region; the sum of these scores gives the overall PASI score. Higher scores indicate more severe disease. PASI is a static assessment made without reference to previous scores. Analyses were done using multiple imputation. Baseline to Week 12
Secondary Percent of Subjects With a PGA Score of 0 or 1 at Week 12. Analyses Were Done Using Multiple Imputation. The PGA is a clinical tool for assessing the current state/severity of a subject's psoriasis at a given timepoint. A static 5-point scale is used to grade lesions on the clinical characteristics of erythema, scaling, and plaque thickness/elevation. The PGA ranges from 0 to 4, and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher PGA scores represent more severe disease. Analyses were done using multiple imputation. Baseline to Week 12
Secondary Mean Change in Percent of Total Body Surface Area (%BSA) Affected From Baseline to Week 12 Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage [Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)]. Estimates of the % involvement in each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall. Baseline to Week 12
Secondary Percent of Subjects With =90% Improvement in PASI Score From Baseline to Week 12. Analyses Were Done Using Multiple Imputation. The Psoriasis Area and Severity Index (PASI) scoring system combines the assessment of lesion severity and extent of affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, and legs). Each area is assessed for 3 signs: erythema (redness), induration (plaque thickness), and scale. The severity of each sign in each body area is assessed and scored independently using a 5-point scale, where 0=none, 1=slight, 2=mild, 3=moderate, 4=severe. Each area is also assessed for percent of skin involved: 0 = (0%), 1 = (1-<10%), 2 = (10-<30%), 3 = (30-<50%), 4 = (50 -<70%), 5 = (70-<90%), 6 = (90-100%). The individual scores are multiplied by a weighted factor for each body region; the sum of these scores gives the overall PASI score. Higher scores indicate more severe disease. PASI is a static assessment made without reference to previous scores. Analyses were done using multiple imputation. Baseline to Week 12
See also
  Status Clinical Trial Phase
Completed NCT01194219 - Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis Phase 3
Recruiting NCT06030076 - A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
Completed NCT04263610 - Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy Phase 4
Completed NCT02601469 - Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis Phase 2
Completed NCT05600036 - A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis Phase 2
Completed NCT05375955 - A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. Phase 2
Completed NCT03614078 - A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis Phase 2
Not yet recruiting NCT05036889 - A 16-week Randomized Evaluation of the Impact of Mind.Px Application on Response to Biologic Treatment in Patients Suffering From Plaque Psoriasis Through Clinical Utility and Health Outcomes. N/A
Completed NCT04603027 - A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis Phase 2
Completed NCT03638258 - The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis Phase 2
Completed NCT02881346 - Efficacy and Tolerability of Enstilar® in Daily Practice
Recruiting NCT02611349 - Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis Phase 3
Completed NCT02251678 - Evaluate the Effect of Elimune Capsules Phase 1
Completed NCT01987843 - Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis Phase 2
Terminated NCT01708629 - Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects Phase 3
Completed NCT01230138 - Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis Phase 2
Withdrawn NCT00747032 - To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis Phase 3
Completed NCT00581100 - Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis Phase 4
Suspended NCT01228656 - Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate Phase 2
Completed NCT00540618 - A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis Phase 2